9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma

Estimated reading time: < 1 min

Condition

Pleural Mesothelioma

Estimated Enrollment: 15

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: IRB15-1149

Study First Received: February 29, 2016

Last Updated: December 28, 2016

Estimated Primary Completion Date: March 2018

Primary Outcome Measures:

Gamma-Interferon Gene Expression profile (GEP) response rate defined as an increase beyond the median value of the sum of individual genes|Number of participants with adverse events as measured by CTCAEv4.0

Sponsors and Collaborators:

University of Chicago

Result Received: No Study Results Posted

Website Link: https://ClinicalTrials.gov/show/NCT02707666

Was this article helpful?
Views: 68